Diplomat Pharmacy (DPLO) Shares are Down -4.11%

Diplomat Pharmacy (DPLO) : During the past 4 weeks, traders have been relatively bearish on Diplomat Pharmacy (DPLO), hence the stock is down -12.43% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -4.27% relative to the S&P 500. The 4-week change in the price of the stock is -12.9% and the stock has fallen -4.11% in the past 1 week.

The stock has recorded a 20-day Moving Average of 7.81% and the 50-Day Moving Average is 15.01%.The 200 Day SMA reached 11.37%


Diplomat Pharmacy (NYSE:DPLO): After opening at $27, the stock dipped to an intraday low of $26.911 on Friday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $28.33 and the buying power remained strong till the end. The stock closed at $28.01 for the day, a gain of 3.74% for the day session. The total traded volume was 882,481. The stocks close on the previous trading day was $28.01.

Diplomat Pharmacy (DPLO) : The most positive equity analysts on Diplomat Pharmacy (DPLO) expects the shares to touch $42, whereas, the least positive believes that the stock will trade at $33 in the short term. The company is covered by 10 Wall Street Brokerage Firms. The average price target for shares are $38 with an expected fluctuation of $2.71 from the mean.

Diplomat Pharmacy, Inc. (Diplomat) is an independent specialty pharmacy in the United States. The Company provides specialty pharmacy support services to a national network of retailers and independent pharmacy groups, hospitals and health systems. The Company offers services in Specialty Drug Dispensing, which includes its specialty infusion pharmacy services. The specialty drug dispensing services include Patient Care Coordination, Clinical Services, Compliance and Persistency Programs, Patient Financial Assistance, Specialty Pharmacy Training/Consulting (Diplomat University), Benefits Investigation, Prior Authorization, Risk Evaluation and Medication Strategy (REMS), Retail Specialty Services, Hospital and Health System Services and Hub Services. The Company help patients adhere to complicated medication therapies, process refills and manage any side effects and insurance concerns to ensure they get the standard of care.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.